Kristy Wolniak

Dr. Kristy Wolniak

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2013 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
KWKristy Wolniak
Kristy Wolniak
CGCharles L. Goolsby
Charles L. Goolsby
YCYi-Hua Chen
Yi-Hua Chen
ACAnjen Chenn
Anjen Chenn
SSSeema Singhal
Seema Singhal
LPLoAnn C. Peterson
LoAnn C. Peterson
Clonal expansions of large granular lymphocytes (LGLs) have been identified in patients following stem cell transplants and may represent posttransplant LGL leukemias or reactive immune responses. To differentiate between these 2 possibilities, we assessed peripheral blood and bone marrow of patients with myeloma after autologous stem cell transplant. All patients examined shortly after autologous stem cell transplant had significant increases in the LGLs in the peripheral blood and bone marrow (71% of lymphocytes) as compared with controls (39%). This increase was detectable years after transplant. The LGLs had a reproducible immunophenotype of CD8+CD57+ T cells without phenotypic abnormalities in 19 of 20 patients. Sixty-five percent of the post-autologous stem cell transplant patients had clonal T-cell receptor gene rearrangements in the bone marrow, yet no patients had neutropenia or splenomegaly. Although the LGL expansions were clonal and persistent, the lack of clinical sequelae suggests the clonal LGL expansion is a reactive, potentially beneficial, immune response to autologous stem cell transplant.

21 July 2020 in ACS Central Science
Verified
Journal Article
Closed access
ATAriel H. Thames
Ariel H. Thames
KWKristy Wolniak
Kristy Wolniak
SSSamuel I. Stupp
Samuel I. Stupp
MJMichael C. Jewett
Michael C. Jewett

1 July 2016 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Open access
PDF file
KWKristy Wolniak
Kristy Wolniak
CGCharles Goolsby
Charles Goolsby
SCSarah Choi
Sarah Choi
AAAsma Ali
Asma Ali
NSNina Serdy
Nina Serdy
MSMaryalice Stetler‐Stevenson
Maryalice Stetler‐Stevenson
Background: Thorough review of current workload, staffing, and testing practices in clinical laboratories allows for optimization of laboratory efficiency and quality. This information is largely missing with regard to clinical flow cytometry laboratories. The purpose of this survey is to provide comprehensive, current, and accurate data on testing practices and laboratory staffing in clinical laboratories performing flow cytometric studies.Methods: Survey data was collected from flow cytometry laboratories through the ASCP website. Data was collected on the workload during a 1‐year time period of full‐time and part‐time technical and professional (M.D./D.O./Ph.D. or equivalent) flow cytometry employees. Workload was examined as number of specimens and tubes per full time equivalent (FTE) technical and professional staff. Test complexity, test result interpretation, and reporting practices were also evaluated.Results: There were 205 respondent laboratories affiliated predominantly with academic and health system institutions. Overall, 1,132 FTE employees were reported with 29% professional FTE employees and 71% technical. Fifty‐one percent of the testing performed was considered high complexity and 49% was low complexity. The average number of tubes per FTE technologist was 1,194 per year and the average number of specimens per FTE professional was 1,659 per year. The flow cytometry reports were predominantly written by pathologists (57%) and were typically written as a separate report (58%).Conclusions: This survey evaluates the overall status of the current practice of clinical flow cytometry and provides a comprehensive dataset as a framework to help laboratory departments, directors, and managers make appropriate, cost‐effective staffing decisions. © 2016 International Clinical Cytometry Society

22 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
LCLauren P. Chrisman
Lauren P. Chrisman
PTPayton F Trimark
Payton F Trimark
YPYanzhen Pang
Yanzhen Pang
DPDavid Randall Pease
David Randall Pease
MMMaria Estela Martinez-Escala
Maria Estela Martinez-Escala
JGJoan Guitart
Joan Guitart
Comparison of the 2007 EORTC/ISCL and the 2022 EORTC/ISCL/USCLC blood staging guidelines for cutaneous T-cell lymphoma at a single institution reveals the newer guidelines fail to detect a subset of patients with Sézary syndrome with low blood burden.

1 June 2020 in Academic Medicine
Verified
Journal Article
Closed access
SHShahzeb Hassan
Shahzeb Hassan
PRPaavani Reddy
Paavani Reddy
KWKristy Wolniak
Kristy Wolniak

29 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
LFLucy Fu
Lucy Fu
PTPayton F Trimark
Payton F Trimark
YLYijie Liu
Yijie Liu
HTHamza Tariq
Hamza Tariq
QCQing Chen
Qing Chen
KWKristy Wolniak
Kristy Wolniak
Background/Objectives: Mycosis fungoides (MF) and Sézary syndrome (SS) are cutaneous T-cell lymphomas (CTCLs) with variable clinical outcomes. Peripheral blood (PB) involvement in MF/SS is an independent predictor of prognosis. Accurate laboratory determination of PB involvement by MF/SS cells, however, is an ongoing challenge. Both flow cytometry (FC) and morphology-based quantification are limited by the overlap of CTCL cells and reactive T-cells. This study looks at the optimization over time of CTCL blood burden evaluation. Methods: This retrospective study reviews CTCL blood assessment at Northwestern Memorial Hospital from 2012 to 2021. Test ordering and reporting practices for morphology-based Sézary cell counts and FC were evaluated. For each assay, quantitative and qualitative results were analyzed and compared including percentages and absolute counts of abnormal T-cell populations and pathologist interpretations. Results: A total of 514 patients were evaluated, with increasing numbers of both tests ordered over time. FC quantitative metrics showed a moderate to high correlation with morphology metrics, especially for absolute CD4+/CD7− counts (correlation coefficient = 0.901, p-value < 0.001). Qualitative pathologist interpretations had moderate agreement between methods (kappa = 0.58). The recent addition of TRBC1 clonality assessment to our FC assay further optimizes the evaluation for CTCL blood burden. Conclusions: Flow cytometry offers a reliable approach for blood staging in MF/SS, and morphologic assessment may be redundant. This study provides a foundation for designing a new FC approach with TRBC1. This comprehensive review of the evolution of our laboratory practices may serve as a guide for other institutions with similar clinical needs.